Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
- Revenue in USD (TTM)44.35bn
- Net income in USD3.29bn
- Incorporated1992
- Employees83.50k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Neogene Therapeutics | 0.18% | -- |
| Neogene Therapeutics Inc | 0.27% | 320.00m |
| TeneoTwo Inc | 2.52% | 1.27bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.32bn | 6.55bn | 124.47bn | 25.20k | 19.24 | 34.00 | 12.49 | 4.73 | 12.12 | 12.12 | 48.66 | 6.86 | 0.4169 | 1.42 | 5.03 | 1,044,564.00 | 10.38 | 11.14 | 13.32 | 13.81 | 75.66 | 77.99 | 24.89 | 28.79 | 1.10 | 7.21 | 0.9141 | 53.53 | 1.32 | 2.87 | 11.18 | -4.10 | 7.11 | 11.03 |
| Bristol-Myers Squibb Co | 46.16bn | 6.33bn | 140.58bn | 34.30k | 22.69 | 4.47 | 8.46 | 3.05 | 2.95 | 2.95 | 21.51 | 14.97 | 0.4479 | 4.54 | 5.72 | 1,345,744.00 | 6.16 | 2.80 | 7.82 | 3.45 | 78.18 | 75.49 | 13.75 | 6.98 | 1.14 | 6.39 | 0.5582 | 148.90 | -0.4872 | 17.31 | -9.54 | 10.14 | 1.17 | 6.72 |
| AstraZeneca plc (ADR) | 44.35bn | 3.29bn | 209.40bn | 83.50k | 63.83 | 5.63 | 24.50 | 4.72 | 1.05 | 1.05 | 14.21 | 11.95 | 0.4394 | 1.29 | 4.40 | 531,137.80 | 3.26 | 2.63 | 4.31 | 3.62 | 80.13 | 78.99 | 7.42 | 6.35 | 0.6806 | 6.81 | 0.441 | 187.07 | 18.53 | 14.57 | 2,835.71 | 6.63 | 9.68 | -- |
| Pfizer Inc. | 100.33bn | 31.37bn | 226.79bn | 83.00k | 7.34 | 2.36 | 6.22 | 2.26 | 5.47 | 5.47 | 17.50 | 17.03 | 0.5299 | 3.83 | 8.95 | 1,208,807.00 | 16.58 | 8.77 | 21.41 | 11.07 | 65.52 | 70.32 | 31.30 | 24.35 | 1.00 | 20.63 | 0.272 | 57.53 | 23.43 | 13.81 | 39.95 | 21.38 | 7.86 | 4.56 |
| Merck & Co Inc | 59.28bn | 14.52bn | 264.60bn | 69.00k | 18.24 | 5.75 | 14.35 | 4.46 | 5.71 | 5.71 | 23.32 | 18.12 | 0.5518 | 2.90 | 6.35 | 859,173.90 | 13.52 | 9.40 | 17.44 | 12.60 | 70.98 | 71.35 | 24.50 | 18.84 | 1.23 | 9.75 | 0.3999 | 71.79 | 21.72 | 8.12 | 17.61 | 23.67 | 18.37 | 3.48 |
| AbbVie Inc | 58.05bn | 11.78bn | 273.97bn | 50.00k | 23.43 | 15.92 | 13.46 | 4.72 | 6.63 | 6.63 | 32.66 | 9.75 | 0.4069 | 4.93 | 5.47 | 1,161,080.00 | 8.30 | 7.57 | 10.74 | 9.68 | 71.53 | 71.58 | 20.40 | 18.43 | 0.8424 | 9.29 | 0.7854 | 97.86 | 3.30 | 15.52 | 2.74 | 15.70 | 5.61 | 17.11 |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2022 | 68.59m | 2.21% |
| Wellington Management Co. LLPas of 31 Dec 2022 | 54.61m | 1.76% |
| PRIMECAP Management Co.as of 31 Dec 2022 | 44.99m | 1.45% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2022 | 40.80m | 1.32% |
| GQG Partners LLCas of 31 Dec 2022 | 17.20m | 0.56% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2022 | 16.56m | 0.53% |
| CIBC Private Wealth Advisors, Inc.as of 31 Dec 2022 | 10.77m | 0.35% |
| Franklin Advisers, Inc.as of 31 Dec 2022 | 10.74m | 0.35% |
| Fisher Asset Management LLCas of 31 Dec 2022 | 8.70m | 0.28% |
| T. Rowe Price International Ltd.as of 31 Dec 2022 | 8.47m | 0.27% |
